1. The University of Texas MD Anderson Cancer Center, Houston, TX;
2. Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea;
3. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL;
4. Charité, Universitätsmedizin Berlin, Berlin, Germany;
5. Cedars-Sinai Medical Center, Los Angeles, CA;
6. Singapore General Hospital, Duke–National University of Singapore (NUS) Medical School, Singapore;
7. Centre Hospitalier Lyon-Sud, Pierre-Bénite, Lyon, France;
8. Centre for Haematology, Imperial College, London, United Kingdom;
9. Winship Cancer Institute of Emory University, Atlanta, GA;
10. Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;
11. Dana-Farber Cancer Institute, Boston, MA;
12. S. Eugenio Hospital, Tor Vergata University, Rome, Italy;
13. Service d’Hématologie Adulte et Centre d’Investigation Clinique, Hôpital Saint Louis, Paris, France;
14. Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy;
15. III. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany;
16. University of Milano-Bicocca/San Gerardo Hospital, Monza, Italy;
17. ARIAD Pharmaceuticals, Inc., Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
18. Centre d’Investigation Clinique (CIC) 1402, INSERM, Poitiers, France;
19. Centre Hospitalier Universitaire de Poitiers, Poitiers, France;
20. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;
21. Hematology/Oncology, Jena University Hospital, Jena, Germany;
22. University of Adelaide/South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia; and
23. Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA